FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130817717> ?p ?o ?g. }

• W3130817717 abstract "Background: Pulmonary arterial hypertension (PAH) is a life-threatening and deteriorating disease with no promising therapy available currently due to its diversity and complexity. An imbalance between vasoconstriction and vasodilation has been proposed as the mechanism of PAH. Angiotensin-converting enzyme 2 (ACE2), which catalyzes the hydrolysis of the vasoconstrictor angiotensin (Ang) II into the vasodilator Ang-(1-7), has been shown to be an important regulator of blood pressure and cardiovascular diseases. Herein we hypothesized diminazene aceturate (DIZE), an ACE2 activator, could ameliorate the development of PAH and pulmonary vascular remodeling. Methods: A murine model of PAH was established using left pneumonectomy (PNx) on day 0 followed by injection of a single dose of the VEGF receptor-2 inhibitor SU5416 (25 mg/kg) subcutaneously on day 1. All hemodynamic and biochemical measurements were done at the end of the study on day 42. Animals were divided into 4 groups ( n = 6–8/group): (1) sham-operated group, (2) vehicle-treatment group (SuPNx 42 ), (3) early treatment group (SuPNx 42 /DIZE 1−42 ) with DIZE at 15 mg/kg/day, subcutaneously from day 1 to day 42, and (4) late treatment group (SuPNx 42 /DIZE 29−42 ) with DIZE from days 29–42. Results: In both the early and late treatment groups, DIZE significantly attenuated the mean pulmonary artery pressure, pulmonary arteriolar remodeling, and right ventricle brain natriuretic peptide ( BNP), as well as reversed the overexpression of ACE while up-regulating the expression of Ang-(1-7) when compared with the vehicle-treatment group. In addition, the early treatment group also significantly decreased plasma BNP and increased the expression of eNOS. Conclusions: ACE2 activator has therapeutic potentials for preventing and attenuating the development of PAH in an animal model of left pneumonectomy combined with VEGF inhibition. Activation of ACE2 may thus be a useful therapeutic strategy for the treatment of human PAH." @default.
• W3130817717 created "2021-03-01" @default.
• W3130817717 creator A5007376349 @default.
• W3130817717 creator A5007695335 @default.
• W3130817717 creator A5024624236 @default.
• W3130817717 creator A5030253390 @default.
• W3130817717 creator A5041835966 @default.
• W3130817717 creator A5062817352 @default.
• W3130817717 creator A5075838887 @default.
• W3130817717 creator A5081587269 @default.
• W3130817717 date "2021-02-19" @default.
• W3130817717 modified "2023-10-17" @default.
• W3130817717 title "Angiotensin-Converting Enzyme 2 Activator Ameliorates Severe Pulmonary Hypertension in a Rat Model of Left Pneumonectomy Combined With VEGF Inhibition" @default.
• W3130817717 cites W1605266378 @default.
• W3130817717 cites W1866413456 @default.
• W3130817717 cites W1976735273 @default.
• W3130817717 cites W1981013779 @default.
• W3130817717 cites W1988174091 @default.
• W3130817717 cites W2005942723 @default.
• W3130817717 cites W2007289750 @default.
• W3130817717 cites W2008054951 @default.
• W3130817717 cites W2013990588 @default.
• W3130817717 cites W2029033950 @default.
• W3130817717 cites W2037985064 @default.
• W3130817717 cites W2043841603 @default.
• W3130817717 cites W2044534634 @default.
• W3130817717 cites W2045826243 @default.
• W3130817717 cites W2047041858 @default.
• W3130817717 cites W2058006596 @default.
• W3130817717 cites W2061564804 @default.
• W3130817717 cites W2071857547 @default.
• W3130817717 cites W2082133861 @default.
• W3130817717 cites W2090894557 @default.
• W3130817717 cites W2113554645 @default.
• W3130817717 cites W2115255579 @default.
• W3130817717 cites W2118074470 @default.
• W3130817717 cites W2146149181 @default.
• W3130817717 cites W2146234408 @default.
• W3130817717 cites W2148960120 @default.
• W3130817717 cites W2155118902 @default.
• W3130817717 cites W2156240908 @default.
• W3130817717 cites W2159858352 @default.
• W3130817717 cites W2172186904 @default.
• W3130817717 cites W2326299596 @default.
• W3130817717 cites W2335117204 @default.
• W3130817717 cites W2566686251 @default.
• W3130817717 cites W2778600864 @default.
• W3130817717 cites W2792389757 @default.
• W3130817717 cites W2808672927 @default.
• W3130817717 cites W2809338703 @default.
• W3130817717 cites W2904180601 @default.
• W3130817717 cites W2905582258 @default.
• W3130817717 cites W2969510145 @default.
• W3130817717 cites W2999197468 @default.
• W3130817717 cites W3017331996 @default.
• W3130817717 cites W3027341161 @default.
• W3130817717 cites W3088572719 @default.
• W3130817717 doi "https://doi.org/10.3389/fmed.2021.619133" @default.
• W3130817717 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7933511" @default.
• W3130817717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33681251" @default.
• W3130817717 hasPublicationYear "2021" @default.
• W3130817717 type Work @default.
• W3130817717 sameAs 3130817717 @default.
• W3130817717 citedByCount "7" @default.
• W3130817717 countsByYear W31308177172021 @default.
• W3130817717 countsByYear W31308177172022 @default.
• W3130817717 countsByYear W31308177172023 @default.
• W3130817717 crossrefType "journal-article" @default.
• W3130817717 hasAuthorship W3130817717A5007376349 @default.
• W3130817717 hasAuthorship W3130817717A5007695335 @default.
• W3130817717 hasAuthorship W3130817717A5024624236 @default.
• W3130817717 hasAuthorship W3130817717A5030253390 @default.
• W3130817717 hasAuthorship W3130817717A5041835966 @default.
• W3130817717 hasAuthorship W3130817717A5062817352 @default.
• W3130817717 hasAuthorship W3130817717A5075838887 @default.
• W3130817717 hasAuthorship W3130817717A5081587269 @default.
• W3130817717 hasBestOaLocation W31308177171 @default.
• W3130817717 hasConcept C120770815 @default.
• W3130817717 hasConcept C126322002 @default.
• W3130817717 hasConcept C134018914 @default.
• W3130817717 hasConcept C178853913 @default.
• W3130817717 hasConcept C185592680 @default.
• W3130817717 hasConcept C198710026 @default.
• W3130817717 hasConcept C2775946041 @default.
• W3130817717 hasConcept C2777714996 @default.
• W3130817717 hasConcept C2778921608 @default.
• W3130817717 hasConcept C2779134260 @default.
• W3130817717 hasConcept C2779961880 @default.
• W3130817717 hasConcept C2780930700 @default.
• W3130817717 hasConcept C2780940725 @default.
• W3130817717 hasConcept C2908929049 @default.
• W3130817717 hasConcept C29323129 @default.
• W3130817717 hasConcept C3008058167 @default.
• W3130817717 hasConcept C524204448 @default.
• W3130817717 hasConcept C71924100 @default.
• W3130817717 hasConcept C84393581 @default.
• W3130817717 hasConcept C98274493 @default.
• W3130817717 hasConceptScore W3130817717C120770815 @default.
• W3130817717 hasConceptScore W3130817717C126322002 @default.
• W3130817717 hasConceptScore W3130817717C134018914 @default.

• next